Agios Pharmaceuticals | AGIO - Interest Expense On Debt


Agios Pharmaceuticals reported $1.39B in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Arrowhead Research USD 22.5M 811K Dec/2025
Astellas Pharma JPY 3.91B 320M Mar/2025
AstraZeneca USD 484M 181M Dec/2025
Bayer EUR 762M 267M Sep/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Incyte USD 582K 10K Dec/2025
Ionis Pharmaceuticals USD 18M 1000K Sep/2025
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Nektar Therapeutics USD 6.02M 420K Sep/2024
Novartis USD 281M 8M Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025